Navigation Links
ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
Date:11/3/2008

MINNEAPOLIS, Nov. 3 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced completion of the final feasibility milestone in the development of the ATS Forcefield(TM) technology. The animal feasibility study has been completed with positive results regarding the inhibition of platelet adhesion on mechanical heart valve prostheses.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

This technology has been the focus of presentations at the American Society for Artificial Internal Organs Conference (ASAIO) in June and at the European Association for Cardio-Thoracic Surgeons (EACTS) meeting in September. Previously, Dr. Mark Slaughter, Professor and Chief of Cardiothoracic Surgery at the University of Louisville and Jewish Hospital presented his findings in an acute human trial with excellent results. Adding to this foundation of positive results, ATS has just completed a 90-day animal feasibility study that has demonstrated the longer term sustained effect of Forcefield on a functioning mechanical heart valve implanted in the mitral position. Examination of the surviving animals confirmed essentially zero presence of platelets on the surface of the heart valves after 90 days without the use of anti-coagulation treatment.

The combination of in vitro human blood results, acute human study results, and now this longer-term functioning heart valve in an animal model supports our view that the novel Forcefield technology will prove effective and broadly applicable. The next steps will be in preparation for human feasibility trials
'/>"/>

SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Equity Research, Inc.,(Scimitar) issues a review of Neurobiological ... Treatments, Look at One Stroke,Drug at a Time; ... available at our website: http://www.scimitarequity.com ., ... in the business of acquiring and developing central ...
... Feb. 14 BiPar Sciences, Inc., a,privately held ... Huh, M.D., Ph.D., has been appointed,President and Chief ... on,March 3, 2008., Dr. Huh previously served ... Business Unit at Nektar Therapeutics, a drug development ...
... 14 GeoPharma, Inc. (Nasdaq:,GORX) announced record revenues ... than a 200% increase in sales sequentially, as ... month periods ending,December 31, 2007., "We are ... the,third quarter of our 2008 fiscal year; it ...
Cached Biology Technology:Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc. 2BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer 2GeoPharma Announces Record Revenues in Third Quarter Results 2GeoPharma Announces Record Revenues in Third Quarter Results 3GeoPharma Announces Record Revenues in Third Quarter Results 4GeoPharma Announces Record Revenues in Third Quarter Results 5GeoPharma Announces Record Revenues in Third Quarter Results 6
(Date:5/23/2013)... at Rollins School of Public Health at Emory ... of Technology, have received a $4 million grant ... at Emory University (Health and Exposome Research Center: ... exposome-based center grant awarded in the United States. ... the National Institute of Environmental Health Sciences (NIEHS) ...
(Date:5/23/2013)... Given the implications for the overall health, ... play a primary role in ensuring that all ... 60 minutes per day of vigorous or moderate-intensity ... Institute of Medicine. Recent estimates suggest that ... evidence-based guideline for promoting better health and development. ...
(Date:5/23/2013)... in treating cerebral palsy with autologous cord blood. Following ... year old boy had been in a persistent vegetative ... months after treatment with the cord blood containing stem ... the child learned to speak simple sentences and to ... study, dispel the long-held doubts about the effectiveness of ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... VALLEY, Pa., June 1, 2009 Olympus America Inc. ... NIR, a biliary metallic stent designed with exceptional anatomic ... NIRflex cell design provides a physician support and flexibility; ... pancreatic, liver and bile duct cancers. ...
... how different species are likely to respond to climate ... a species and the interactions between species, in the ... of BioScience , by Eric Post of Pennsylvania ... can be avoided. Their approach, which relies on multi-stage ...
... our cells possess an internal clock, a group of genes ... a day. A large number of circadian genes are expressed ... be precisely regulated over the course of the day. A ... Research Frontiers in Genetics, based at the University of Geneva, ...
Cached Biology News:MicroRNAs grease the cell's circadian clockwork 2
... quick and easy operation of a wide ... The software is fully secure and ... Part 11 regulations, and compatible with user-created ... versatility enables use in high-level research and ...
... We can introduce random mutations to the ... be then cloned into a vector of choice ... Mutation frequency can be set to a ... Number of clones 106-108. Mutations can be ...
... The Freedom EVOlyzer is Tecans new Enzyme-Linked ... microplate processing. Freedom EVOlyzer is a dedicated ... state-of-the art reader, washer and incubation units ... The Freedom EVOlyzer is available in three ...
... The Digital Clamp One can operate as ... as a Conductance (Dynamic) Clamp in electrophysiology research ... as good as conventional analog equipment. This ... advances in the capabilities of Digital Signal Processing ...
Biology Products: